Figure 1

miR-26a-5p regulated VEGF-A in cultured human podocytes. (A) Expression of miR-26a-5p in cultured human podocytes (h. PODs) and human glomerular endothelial cells (h. GECs). Expression levels are given as fold change compared to h. GECs. ***p < 0.001. (B) TaqMan qPCR for miR-26a-5p in cultured human podocytes 72 h after a 4 h transfection with a miR-26a-5p mimic (miR-26a-5p) compared to a miR control (miR-CTRL) and untransfected condition (WT). ***p < 0.001. (C) Fold change in relative VEGF-A mRNA expression in cultured human podocytes 72 h after a 4 h transfection with a miR-26a-5p mimic (miR-26a-5p) compared to a miR control (miR-CTRL) and untransfected condition (WT). **p < 0.001. (D Western blot for VEGF-A in cultured human podocytes 72 h after a 4 h transfection with a miR-26a-5p mimic (miR-26a-5p) compared to a miR control (miR-CTRL) and untransfected condition (WT). (E) Quantification of western blot bands shown in 1G. Statistic was done with three independent blots shown in supplementary Fig. 2. The band with the highest density of the each blot was set to be 100%. ***p < 0.001. (F) Cytoskeleton rearrangement after transfection on cultured human podocytes with a miR-26a-5p mimic (miR-26a-5p) or a control miR mimic (miR-CTRL). Actin fibers were visualised using Alexa Fluor® 546 phalloidin (red). Size bar = 20µm. (G) Two different binding sites of miR-26a-5p seed region to PIK3C2α predicted by FINDTAR3. (H) Fold change in relative PIK3C2α mRNA expression in cultured human podocytes 72 h after a 4 h transfection with a miR-26a-5p mimic (miR-26a-5p) compared to a miR control (miR-CTRL) and untransfected condition (WT). **p < 0.001.